United Kingdom

Cancer Genetics Inc (CGIX.OQ)

CGIX.OQ on NASDAQ Stock Exchange Capital Market

14 Dec 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Cancer Genetics Q3 loss per share $0.15
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Cancer Genetics Inc :Cancer genetics reports record third quarter 2017 revenue and 134% increase in contracted bookings from major biotech and pharmaceutical companies.Q3 loss per share $0.15.Q3 revenue $8.0 million versus i/b/e/s view $7.9 million.Q3 earnings per share view $-0.12 -- Thomson Reuters I/B/E/S.Cancer genetics inc - ‍integration of vivopharm acquisition is on-track and will deliver a full quarter of results and additional revenue in q4 of 2017​.  Full Article

Cancer Genetics receives New York state approval for Focus::Myeloid NGS-based panel
Wednesday, 17 Aug 2016 

Cancer Genetics Inc :Received New York state approval for its Focus::Myeloid NGS-based panel for Myeloid malignancies.  Full Article

Cancer Genetics Q1 revenue rose 39 pct to $6.1 mln
Tuesday, 10 May 2016 

Cancer Genetics Inc : Cancer Genetics Inc announces 39% revenue increase and provides recent company highlights .Q1 revenue rose 39 percent to $6.1 million.  Full Article